Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs)
The press release of 16 November 2020 (released at 08:31:34) stated incorrectly that the trading in BTAs in Scandion Oncology’s rights issue starts on 3 December 2020. The correct date for the start of trading in BTAs is 26 November 2020 and the trading will be ongoing until the Danish Business Authority has registered the rights issue and BTAs are converted to shares. Below is the correct preliminary timetable for the rights issue.
Preliminary timetable for the rights issue
|Last day of trading in shares including right to receive subscription rights:||2020-11-20|
|First day of trading in shares excluding right to receive subscription rights:||2020-11-23|
|Record date for participation in the rights issue:||2020-11-24|
|Prospectus announced and published on the Company's web page:||2020-11-24|
|Subscription period:||26 November – 10 December 2020|
|Trading in subscription rights:||26 November – 8 December 2020|
|Trading in BTAs ends:||26 November 2020 until the Danish Business Authority has registered the rights issue and BTAs are converted to shares.|
|Announcement of final outcome in the rights issue:||Around 15 December 2020.|
|Trading in new shares commences:||Following registration of the new shares at the Danish Business Authority, the newly issued shares will be admitted to trading on Spotlight. Such trading is expected to commence around 11 January 2021.|
For further information, please contact:
Bo Rode Hansen, CEO
Phone: +45 38 10 20 17
The information was provided by the contact person above for publication on 17 November 2020.
About Scandion Oncology
Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Ticker code: SCOL
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Scandion Oncology in any jurisdiction, either from Scandion Oncology or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (“the Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus will be prepared by the Company and published on the Company’s website after the prospectus has been reviewed and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). In Denmark, the offering is carried out without a prospectus pursuant to applicable exemptions.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
This press release contains forward-looking statements related to the Company’s intentions, estimates or expectations with regard to the Company’s future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Spotlight Stock Market’s regulations.
Penser Access: Surgical Science - Stärker sig emot kommande skifte inom kirurgin
SUS förvärvar bolaget Mimic för USD 18m+ USD 15,6m i potentiell earnout. Genom förvärvet får SUS ytterligare två större kunder inom robotkirurgi, Medtronic som väntas ansöka om CE- märkning Q1'21 och Medicaroid, en utmanare med regulatoriskt godkännande i Japan. Vi sänker våra estimat för EPS 2021 m...
Ny vetenskaplig publikation om klinisk studie med PExA
Forskaren som ligger bakom utvecklingen av PExAs metod, Professor Anna-Carin Olin har tillsammans med medarbetare vid AMM inom Sahlgrenska Akademin, med PExAs metod för insamling av biomaterial i utandningsluften undersökt 200 deltagare i en stor internationell studie, ”Europastudien för luftvägar o...
Cline Scientific startar samarbete med globalt läkemedelsbolag med målet att identifiera kärnmekanismer i kärlsjukdomar
Cline Scientific har ingått ett samarbete med AstraZeneca för att använda Clines gradientteknologi som en del av det europeiska MSCA-ITN Network, V.A Cure. V.A Cure är ett Horizon 2020-finansierat projekt som syftar till att avslöja kärnmekanismer för vaskulära anomalier och att utnyttja denna infor...
Cline Scientific initiates collaboration with global biopharmaceutical company with the aim of uncovering core mechanisms of vascular disease
Cline Scientific has entered into a collaboration with AstraZeneca to utilise Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon 2020 funded project which aims to uncover core mechanisms of vascular anomalies and to leverage this infor...